Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Company profile
Ticker
ARAY
Exchange
Website
CEO
Mr. Sandeep Chalke
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
APOGEE ENTERPRISES INC
SEC CIK
Corporate docs
Subsidiaries
Accuray International SARL • Accuray Europe SAS • Accuray UK, Ltd. • Accuray Asia Ltd. • Accuray Japan K.K. • Accuray Korea Limited Company • Accuray Medical Equipment (India) Private Limited • Accuray Medical Equipment (Rus) LLC. • Accuray Medical Equipment GmbH • Accuray Medical Equipment (Canada) Ltd. ...
IRS number
770268932
ARAY stock data
Latest filings (excl ownership)
8-K
Accuray Appoints Michael Murphy as VP, Corporate Controller
21 Oct 24
8-K
Departure of Directors or Certain Officers
15 Oct 24
ARS
2024 FY
Annual report to shareholders
4 Oct 24
DEFA14A
Additional proxy soliciting materials
4 Oct 24
DEF 14A
Definitive proxy
4 Oct 24
10-K
2024 FY
Annual report
19 Sep 24
NT 10-K
Notice of late annual filing
16 Sep 24
8-K
Entry into a Material Definitive Agreement
16 Sep 24
8-K
Departure of Directors or Certain Officers
3 Sep 24
8-K
Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results
14 Aug 24
Transcripts
ARAY
Earnings call transcript
2024 Q4
14 Aug 24
ARAY
Earnings call transcript
2024 Q3
1 May 24
ARAY
Earnings call transcript
2024 Q2
31 Jan 24
ARAY
Earnings call transcript
2024 Q1
7 Nov 23
ARAY
Earnings call transcript
2023 Q4
9 Aug 23
ARAY
Earnings call transcript
2023 Q2
9 Aug 23
ARAY
Earnings call transcript
2023 Q3
26 Apr 23
ARAY
Earnings call transcript
2023 Q2
1 Feb 23
ARAY
Earnings call transcript
2023 Q1
3 Nov 22
ARAY
Earnings call transcript
2022 Q4
11 Aug 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 24 | Jun 23 | Jun 22 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.39 mm | 70.39 mm | 70.39 mm | 70.39 mm | 70.39 mm | 70.39 mm |
Cash burn (monthly) | (no burn) | 1.73 mm | (no burn) | 467.58 k | (no burn) | 992.00 k |
Cash used (since last report) | n/a | 6.51 mm | n/a | 1.76 mm | n/a | 3.73 mm |
Cash remaining | n/a | 63.88 mm | n/a | 68.64 mm | n/a | 66.67 mm |
Runway (months of cash) | n/a | 36.8 | n/a | 146.8 | n/a | 67.2 |
Institutional ownership, Q2 2024
57.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 115 |
Opened positions | 82 |
Closed positions | 5 |
Increased positions | 10 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 101.55 bn |
Total shares | 56.55 mm |
Total puts | 13.10 k |
Total calls | 213.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 8.23 mm | $14.98 bn |
Neuberger Berman | 5.32 mm | $9.68 bn |
Vanguard | 5.26 mm | $9.57 bn |
Heartland Advisors | 3.32 mm | $6.04 bn |
Archon Capital Management | 3.13 mm | $5.69 bn |
Royce & Associates | 2.88 mm | $5.25 bn |
Renaissance Technologies | 2.81 mm | $5.12 bn |
Geode Capital Management | 2.13 mm | $3.88 bn |
Harbert Fund Advisors | 1.85 mm | $3.37 bn |
STT State Street | 1.82 mm | $3.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep 24 | Jesse Chew | Common Stock | Payment of exercise | Dispose F | No | No | 1.8 | 12,831 | 23.10 k | 369,089 |
30 Sep 24 | Michael Hoge | Common Stock | Payment of exercise | Dispose F | No | No | 1.8 | 8,102 | 14.58 k | 382,106 |
30 Sep 24 | Suzanne C Winter | Common Stock | Payment of exercise | Dispose F | No | No | 1.8 | 16,604 | 29.89 k | 1,336,476 |
4 Sep 24 | Ali Pervaiz | Common Stock | Sell | Dispose S | No | No | 2.0557 | 8,404 | 17.28 k | 394,138 |
30 Jun 24 | Suzanne C Winter | Common Stock | Payment of exercise | Dispose F | No | No | 1.76 | 16,731 | 29.45 k | 1,353,080 |
News
Accuray Announced That Results Of The Pace-B– Prostate Advances In Comparative Evidence – Trial Were Published In The New England Journal Of Medicine
17 Oct 24
Accuray Secures CE Mark For Accuray Helix, A CT-Guided Helical Radiotherapy System
27 Aug 24
Accuray's Radixact for Cancer Treatment Debuts in US
15 Aug 24
Russell 2000 Set For Strongest Session In A Month As US Economy Defies Recession Fears: Small Cap Movers On Thursday
15 Aug 24
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
15 Aug 24
Press releases
Accuray Appoints Michael Murphy as VP, Corporate Controller
21 Oct 24
New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer
17 Oct 24
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
15 Oct 24
Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training
30 Sep 24
Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
10 Sep 24